‘Cannabis Not Completely Banned, Medical Use Allowed’: Centre Tells Delhi HC

The court refused to advance the date of hearing of the plea seeking to legalise its use on various grounds including medicinal purposes.

New Delhi: The use of cannabis is not completely banned in the country as its medical and scientific use is allowed under the law, the Union government has told the Delhi high court which, on Monday refused to advance the date of hearing of the plea seeking to legalise its use on various grounds including medicinal purposes.

The bench headed by Justice Rajiv Shakhder refused to allow the early hearing application by the petitioner Great Legalisation Movement India Trust which contended that there were reports to suggest that cannabinoids helped in countering the impact of COVID-19.

“Looking at the broad position, the application can’t be entertained at this junction. We are trying to do whatever is possible,” the bench, also comprising Justice Talwant Singh told counsel for the petitioner, advocate Abhishek Avadhani.

Also read: The Case for Legalising and Regulating Cannabis

The petition, which is listed for further hearing in March, has challenged provisions of the Narcotic Drugs and Psychotropic Substances (NDPS) Act which prohibit the use of cannabis and has contended that the drug has medicinal and industrial benefits.

The petitioner has sought directions to the Union government to frame rules permitting and regulating the use of cannabis, especially for medicinal purposes.

In its affidavit filed last year, the Union government urged the court to dismiss the petition with costs and claimed that it has adopted a balanced approach on cannabis by empowering the state governments to permit, control and regulate the cultivation of any cannabis plant, production, manufacture, possession, transport, import inter-state, export inter-state, sale, purchase, consumption or use of cannabis (excluding charas) for medical, scientific and industrial purposes.

The Union government stated that the present legal framework regulating the usage of cannabis did not violate Articles 14 (right to equality), 19(1)(g) [freedom of trade], 21 (right to life) or other fundamental rights guaranteed under the Constitution.

“There is no complete ban on cannabis under NDPS Act but can be used for medical, scientific, industrial, horticultural purposes by taking requisite permissions from respective state governments,” the affidavit filed by the director, narcotics control, department of revenue, Ministry of Finance said.

“The state governments are empowered to license the cultivation of cannabis for industrial and scientific purpose. On similar lines, it may be inferred that the cultivation for industrial/ horticultural purposes, as provided in Section 14 of NDPS Act, can be considered by the state government,” it added.

While exercising this power, the state of Uttrakhand has allowed the cultivation of hemp for industrial purposes and the hemp-based products are available in the market and also available online, the affidavit informed.

The Centre also submitted that cannabinoids are not a first-line treatment and cautioned against the huge risk of diversion of cannabis for non-medical use.

It highlighted that as per a survey by the ministry of social justice & empowerment, cannabis and opioids are the next commonly used substances in India, after alcohol and at the national level, one in eleven cannabis users suffered from cannabis dependence.

In its response, the Union government further clarified that under the NDPS Act, there was a clear distinction between the various parts of cannabis plant, namely the fibre, flower and the seed and does not treat all of them and their derivative equally.

“The seeds and leave when not accompanied by the tops have not been included in the definition of cannabis. Bhang which is an edible preparation of cannabis is also not controlled under the NDPS Act,” it said.

The petitioner has sought to declare as unconstitutional the provisions in the NDPS Act and Rules which prohibit and criminalise the use of cannabis and prescribe unreasonable restrictions with respect to activities related to it.

The petitioner trust, registered in Karnataka and at the forefront of the movement to decriminalise the use of cannabis, has claimed there is not a single document that shows that it was lethal to humans and emphasises the use of cannabis was legal in several other countries.

(PTI)

The Case for Legalising and Regulating Cannabis

Even though marijuana is prohibited, we can’t seem to make it go away. But it can be made safer.

On November 7, 2019, the Delhi high court sought the government’s stand on a petition filed by the Great Legalisation Movement India Trust to decriminalise the use of cannabis. The petitioner has challenged the provisions of the Narcotics Drugs and Psychotropic Substances Act, 1985 which criminalise the use of cannabis as violative of various provisions of the constitution of India.

The main psychoactive compound in marijuana that gives a “euphoric” sensation is tetrahydrocannabinol (THC). There is evidence to show that THC is related to psychosis. Marijuana also contains a substance called CBD (cannabidiol), which seems to counteract its effect. CBD is a non-psychoactive compound and that means it doesn’t produce the “high/euphoria” associated with THC.

CBD is even being tested as a treatment against psychosis and anxiety. A 2017 King’s College London study found that participants treated with CBD had fewer psychiatric symptoms than those who received a placebo. Dr. Philip McGuire, lead author of the 2017 study, remarked:

“Although it is still unclear exactly how CBD works, it acts in a different way to antipsychotic medication and thus could represent a new class of treatment. Moreover, CBD was not associated with significant side effects. This is also potentially important, as patients may be reluctant to take antipsychotic medication because of concerns about side effects.”

Since CBD doesn’t give you the “high”, growers have gradually decreased the amount of CBD in marijuana over the last few decades, while simultaneously increasing THC levels. Sample testing showed that THC levels have risen from around 4% in the 1990s to nearly 12% in 2014, shifting the ratio of THC to CBD from 1:14 in 1995 to about 1:80 in 2014.

Though it is unclear as to how precise those tests were, recent findings suggest that the more marijuana you consume, and the stronger it is, the higher your risk of developing psychosis. Again, the question of how high the risk of psychosis is for the general population is unclear.

Also read: How Cannabis Jumped from ‘Colonial Science’ to Western Medicine – in Calcutta

A study from Britain found that while marijuana use has risen significantly between 1996 and 2005, the number of schizophrenia cases – a type of psychosis – remained stable. The risk of marijuana-induced psychosis remains the highest for people who already have a high risk of psychosis, to begin with. For them, it seems more likely that marijuana speeds up the development of their condition, rather than causing it.

So the argument goes, if fewer people have access to marijuana, the lower the risk of marijuana-induced psychosis. Agreed, but one could argue, precisely since marijuana is illegal, there is a greater chance people addicted to marijuana will end up with psychosis.

Past experiences with prohibition

Prohibition makes illegal drugs stronger and more potent. This is what happened during the prohibition of alcohol in the US. Although the consumption of alcohol fell at the beginning of the Prohibition, it subsequently increased. Alcohol became more dangerous to consume; crime increased and became “organised”. No measurable gains were made in productivity or reduced absenteeism.

Prohibition removed a significant source of tax revenue and greatly increased government spending. It led many drinkers to switch to opium, marijuana, patent medicines, cocaine, and other dangerous substances that they would have been unlikely to encounter in the absence of Prohibition.

Prohibition also led many people to drink more “legitimate” alcohol, such as patent medicines (which contained high concentrations of alcohol), medicinal alcohol, and sacramental alcohol. One New Jersey businessman claimed that there were ten times more places one could get a drink during Prohibition than there had been before. Potent marijuana with high levels of THC has gained traction over the years.

The numbers also show that stringent laws don’t deter people from using marijuana. A study by Alex Stevens, professor of Criminal Justice at Kent’s School for Social Policy, Sociology and Social Research found there is no evidence to suggest that teenage cannabis use is lower in countries with tougher policies.

Recently another study, ‘2018 Cannabis Price Index’ conducted by ABCD revealed Delhi to be the third-highest consumer of cannabis in the world, only behind New York and Karachi. Mumbai also featured at sixth position on that list. For perspective, pot – legal in Amsterdam  – ranks at a lowly 56th place on the index. We can’t make marijuana go away, but it can be made safer.

An employee tends to a medical cannabis plants at Pharmocann, an Israeli medical cannabis company in northern Israel January 24, 2019. Photo: Reuters/Amir Cohen/File Photo

If marijuana were legal, there would be more options for consumers, and regulators could, for example, insist on a high level of CBD. Just like most people don’t drink an after-work bottle of vodka, many people might gladly consume the after-work beer version of marijuana.

For instance, in most states that have regulated marijuana in the US, only cannabis extract containing no more than 0.5% THC and no less than 10% CBD, by weight is allowed. States like Kentucky have completely banned THC from their permitted extracts. Legalising marijuana could also open the gates to a ton of new research. In 2018, the FDA approved a drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Research is difficult when the drug in itself is illegal.

Gateway drug hypotheses

Another argument suggests that marijuana is a ‘gateway drug‘. This hypothesis states that there is a causal sequence through classes of drugs, whereby the use of “less harmful” substances is a risk factor for using “harder drugs”. There are two proposed reasons for this:

  1. Experimentation: Trying a drug like marijuana increases the taste (and perceived pleasure) for other drugs, leading to further experimentation.
  2. Social groups: When a person using marijuana associates with other people who use marijuana, then it is likely they will become exposed to other drugs and substances too. This means there’s an increased opportunity and access to “heavier” substances.

Research shows that 45% of lifelong marijuana users have taken some other illegal drugs at some point. It can be argued that legalising marijuana could reinforce this trend as if more young people try legal marijuana, they might end up trying harder drugs.

But, the real gateway to drugs come in much earlier. A study showed that tobacco products could act as gateway drugs, opening the door to use of illicit drugs. The likelihood of initiating the use of tobacco or other licit drugs before using illicit drugs is much greater than the opposite process. A report suggests that only 2% of those using both tobacco and cannabis reported having used cannabis before tobacco.

Notwithstanding the same, the issue of cannabis being a gateway drug is much more complex, as multiple confounding factors suggest that a person’s drug usage trajectory might not be linked to previous exposure to cannabis. Instead, subsequent drug choice might be due to the independent characteristics that led the individual to be at risk for using illicit drugs in the first place.

Studies show that certain conditions make people especially vulnerable to drugs and addiction. A troubled childhood, trauma, low social status, depression, loneliness, and even genetics could be factors. To escape these issues, people turn to drugs. Only, drugs don’t solve any of the problems and instead, becomes a new problem. The underlying causes have to be addressed and punishing addicts is not helpful.

Portugal has shown us the lead in tackling this issue. Portugal had one of the worst drug epidemics in the world. This prompted the government to take a novel step. In 2001, it decriminalised all drugs (including heroin). Possession and use of drugs were treated as health issues and not crimes. Anyone caught with less than a ten-day supply of any drug — including heroin — received mandatory medical treatment. With no judge, no courtroom and no jail, the number of drug addicts, the usage of hard drugs and diseases due to overdoes decreased.

A bud of cannabis. Photo: Reuters

Also read: The Juul Comes to School – But Also to the Aid of Adult Smokers in India

On December 11, 2018, Norman Lamb, a former liberal democrat MP moved a bill to legalise possession and consumption of cannabis in England. He raised four major points:

“I want to make four key points. First, nowhere across the world has prohibition worked—cannabis is available everywhere. Secondly, people have no idea what they are buying. We know that leaving supply in the hands of criminals puts teenagers in particular at risk. They are most susceptible to suffering mental health consequences, including psychosis, from regular use of potent strains available on the street.

The widespread use of those dangerous strains is the result of our failure to regulate. A regulated market would allow the Government to control the safety and potency of cannabis sold by legal vendors. Through a misplaced desire to be “tough on drugs”, we leave teenagers vulnerable to exploitation from sellers who have no interest at all in their welfare. Through inaction, Government and Parliament are culpable. If something is potentially dangerous to children and young people, we must control it and regulate it, not leave it freely available from those keen to make a fast buck.

Thirdly, we know that the illegal market for drugs generates extreme violence in many communities, and particularly the most disadvantaged. If a supplier faces competition, they do not resort to the courts to protect their market; they use extreme violence. Thousands of people have lost their lives as a result of illegal trade in drugs in countries such as Mexico, but on the streets of our poorest communities, violence is meted out regularly. Young vulnerable teenagers get caught up in this violent trade and cannot escape. It does not have to be like this.

Fourthly, we still criminalise thousands of people every year, taking up precious police time that could be used to fight serious crime. Careers are blighted for using a substance that no doubt many Members on the Government Benches have used at some stage of their lives. Meanwhile, the most harmful drug of all is consumed in large quantities right here in this building.

Alcohol leads to violence on our streets and behind closed doors in people’s homes. It destroys families up and down our country, yet we tax it, and the Exchequer benefits enormously from it. Is there not dreadful hypocrisy in the fact that we allow our drug of choice while criminalising people who use another, less dangerous drug, many for the relief of pain?”

In response to the above, former Conservative MP Steve Double responded stating:

“My concern is that, by liberalising cannabis use, we would send precisely the wrong message to our young people. We would be giving them the message that cannabis is safe and okay to use. We need to make very clear that cannabis is a dangerous drug and that there is no safe consumption of cannabis in an uncontrolled, unregulated way. We are clearly in the midst of a war on drugs, but we will not win the war by raising the white flag, giving up and surrendering. No war has ever been won by surrendering”

In jurisprudence, the theory of expressive law sees the policy as a device for signalling a moral position or social norm, which may influence behaviour either directly by inducing individuals to internalise that norm and effecting a change in preferences, or, indirectly, by highlighting a particular social equilibrium and influence equilibrium selection.

Also read: Scrutinizing the Future of UK’s Nascent Cannabis Industry

The problem though is Prohibition as expressive law may strengthen adherence to the non-consumption social norm among the ‘establishment’ group, while simultaneously strengthening the dissident identity of the counter-culture group who are at highest risk starting cannabis use. Around 3 million people die every year due to alcohol abuse each year, while smoking kills more than 8 million people. Though legal,  alcohol and tobacco are still portrayed as hazardous substances.

Governance would aid curbing the upsurge in drug abuse. Regulation allows cannabis buyers to moderate their intake. As seen in the case of the US, a patient roster, a list of licensed vendors, substance control (CBD percentage, etc) could be maintained to prevent abuse. Legality creates incentives that drug dealers can’t exploit. Contrary to Steve Double’s view, legalising marijuana does not mean endorsing it. It means taking responsibility for the risks it possesses.

R. Vigneshwar is an advocate practising at the Madras high court.

Centre to Allow Scientific Research on Cannabis

Monitored growth of cannabis will be allowed at the Central Institute of Medicinal and Aromatic Plants in Uttar Pradesh and Uttarakhand.

New Delhi: The Indian government will allow cannabis research for the first time, with the narcotics department sanctioning a research and development project to examine substances found in the plant.

The Vedas speak about cannabis as a sacred plant, but it was banned due to drug abuse. Apart from prohibiting cultivation, sale and possession of the drug, India had also decided not to tap into its potential medical benefits.

Now, the narcotics department within the Union finance ministry has sanctioned a research and development project on compounds such as cannabidiol (CBD) and tetrahydrocannabinol (THC) found in cannabis, commonly known as ganja. While the former is used in gels, oils and has medicinal use, the latter is responsible for the psychoactive effect.

Also Read: How an Ancient Chinese Text Fought Malaria and Won a Nobel, While India Lags Behind

Earlier this year, the World Health Organisation proposed recategorising cannabis in international law due to growing evidence supporting its medical use. A number of countries have also moved to legalise the sale of the drug for medicinal purposes.

The narcotics department’s sanction means that cannabis will be grown in a monitored way, at the Central Institute of Medicinal and Aromatic Plants (CIMAP) in Uttar Pradesh and Uttarakhand.

India doesn’t allow the cultivation of cannabis. Cannabis, coca and opium are prohibited for any general cultivation, consumption or possession under the Narcotic Drugs and Psychotropic Substances Act, 1985. The Act allows cannabis to be used only for medical and scientific purposes.

According to a note released by the government, the plan is for the Council of Scientific and Industrial Research (CSIR) and CIMAP to work on the “genetic improvement of identification and selection of THC, CBD and cannabinioderpene.”

This note has been sent to all state governments as well as the director of narcotics control in the finance ministry.

High levels of THC is responsible for the psychoactive nature of cannabis. Cannabis with low THC content can be used for industrial and horticulture purpose. It can also be used for biomass and production of cannabis seed oil. CBD extracts can be used in oils and food supplements and also has medicinal use.

Last year too, there was talk about medical cannabis being approved in India. When used correctly, it can help to manage pain, cancer, epilepsy and sickle cell anaemia.

Also Read: Indian Science Institute Announces Research on Medical Use of Cannabis

The Indian Institute of Integrative Medicine (IIIM) in Jammu is reportedly working alongside CSIR on this research. The institute plans to conduct clinical trials along with the Tata Memorial Centre (TMC) in Mumbai, the All India Institute of Medical Sciences and a Raipur-based hospital. Some animal trials were conducted previously, and the institute said last year it hoped to get regulatory approval for human trials.

At a recent event organised in partnership with India’s AYUSH ministry, some AYUSH experts pitched for the legal use of medical cannabis, especially in pain management.

Currently, some Indian companies have been using hemp, also made from cannabis but without its drug properties, to make textiles and accessories.

Australia to Allow Medicinal Cannabis Exports to Capture Lucrative Market

Cannabis cultivation in Australia is still relatively small and the government hopes domestic medicinal use, legalised last year, and exports will rapidly boost production.

Medical cannabis crop in Australia (Representative image). Credit: Wikimedia Commons

Sydney: Australia said on Thursday it planned to become the fourth country in the world to legalise medicinal marijuana exports in a bid to score a piece of the estimated $55 billion global market.

Cannabis cultivation in Australia is still relatively small, as recreational use remains illegal. But the government hopes domestic medicinal use, legalised last year, and exports will rapidly boost production.

“Our goal is very clear: to give farmers and producers the best shot at being the world’s number one exporter of medicinal cannabis,” health minister Greg Hunt told reporters in Melbourne.

Shares in the more than a dozen Australian cannabis producers listed on the local exchange soared after the announcement.

Cann Group ended the day up 35%; AusCann Group rose nearly 54%; and BOD Australia closed up about 39%. All were record highs for those companies. Hydroponics Company finished up 30%, hitting its highest price in five weeks.

Peter Crock, chief executive of Cann Group, which cultivates cannabis for medicinal and research purposes, said medicinal marijuana production had been stymied by limited demand from Australian patients.

“While the Australian patient base is growing, it is very small,” Crock told Reuters. “Being able to export will allow us to have the scale to increase production.”

Hunt said the new legislation would include a requirement that growers first meet demand from local patients before exporting the remainder of their crop.

Despite growing demand, only Uruguay, Canada and the Netherlands have so far legalised the export of medicinal marijuana. Israel has said it intends to do so within months.

The Australian government’s proposal needs to pass federal parliament when it returns to session in February. The country’s main opposition Labor Party has signalled it would support the move.

Exports would then likely begin within months.

Fuelled by a growing acceptance of the benefits of marijuana to manage chronic pain, moderate the impact of multiple sclerosis and to soften the effects of cancer treatment, several countries and 29 states in the US have legalised cannabis for medicinal use.

Australia‘s chief commodity forecaster does not publish data on cannabis production, but rough estimates by the University of Sydney estimated the legal industry at A$100 million ($78 million), well below the C$4 billion ($3.19 billion) that Canada estimates its market to be worth.

US consultancy company Grand View Research last year forecast the global medicinal cannabismarket would be worth $55.8 billion by 2025.

($1 = 1.2780 Australian dollars)

($1 = 1.2542 Canadian dollars)

(Reuters)